Aridis Pharmaceuticals https://investors.aridispharma.com/ Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview https://investors.aridispharma.com/2018-11-13-Aridis-Pharmaceuticals-Announces-Third-Quarter-2018-Financial-Results-and-Corporate-Overview - Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market Tue, 13 Nov 2018 07:30:00 -0500 https://investors.aridispharma.com/2018-11-13-Aridis-Pharmaceuticals-Announces-Third-Quarter-2018-Financial-Results-and-Corporate-Overview Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine" https://investors.aridispharma.com/2018-11-07-Aridis-Pharmaceuticals-Announces-Publication-of-Positive-AR-301-Phase-1-2a-Data-in-Intensive-Care-Medicine-and-The-Lancet-Respiratory-Medicine - Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine Wed, 07 Nov 2018 07:30:00 -0500 https://investors.aridispharma.com/2018-11-07-Aridis-Pharmaceuticals-Announces-Publication-of-Positive-AR-301-Phase-1-2a-Data-in-Intensive-Care-Medicine-and-The-Lancet-Respiratory-Medicine Aridis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference https://investors.aridispharma.com/2018-09-26-Aridis-Pharmaceuticals-to-Present-at-the-2018-Cantor-Global-Healthcare-Conference Wed, 26 Sep 2018 08:30:00 -0400 https://investors.aridispharma.com/2018-09-26-Aridis-Pharmaceuticals-to-Present-at-the-2018-Cantor-Global-Healthcare-Conference Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates https://investors.aridispharma.com/2018-09-24-Aridis-Pharmaceuticals-Strengthens-Intellectual-Property-Portfolio-With-Additional-Broad-Patent-Coverage-For-Multiple-Product-Candidates - New patents add to previously issued U.S. and international counterpart patents and patent applications that form Aridis's fully human monoclonal antibody patent portfolio Mon, 24 Sep 2018 07:00:00 -0400 https://investors.aridispharma.com/2018-09-24-Aridis-Pharmaceuticals-Strengthens-Intellectual-Property-Portfolio-With-Additional-Broad-Patent-Coverage-For-Multiple-Product-Candidates Aridis Pharmaceuticals Announces Pricing of Initial Public Offering https://investors.aridispharma.com/2018-08-13-Aridis-Pharmaceuticals-Announces-Pricing-of-Initial-Public-Offering Mon, 13 Aug 2018 19:31:00 -0400 https://investors.aridispharma.com/2018-08-13-Aridis-Pharmaceuticals-Announces-Pricing-of-Initial-Public-Offering